<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04566653</url>
  </required_header>
  <id_info>
    <org_study_id>D9480C00016</org_study_id>
    <nct_id>NCT04566653</nct_id>
  </id_info>
  <brief_title>Patient Palatability and Preference of 3 Potassium Binders in Patients With Chronic Kidney Disease and Hyperkalaemia</brief_title>
  <acronym>APPETIZE</acronym>
  <official_title>Non-Interventional, Exploratory, Phase IV, Single-Blind, Cross-Sectional, Randomised, Cross-over Study Evaluating Patient Palatability and Preference of 3 Potassium Binders in Patients With Chronic Kidney Disease &amp; Hyperkalaemia (APPETIZE).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Covance</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Calyx</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ERT: Clinical Trial Technology Solutions</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medidata Solutions</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This non-interventional, Phase IV, exploratory, cross-over, randomised, single-blind, active&#xD;
      comparator-controlled study has been designed to measure the palatability and preference of&#xD;
      Lokelma® versus Veltassa® versus S/CPS in patients with dialysis and non-dialysis chronic&#xD;
      kidney disease (CKD) and hyperkalaemia (HK). The sponsor hypothesizes that palatability, in&#xD;
      terms of taste, texture, smell, and mouthfeel, will score higher (better) for Lokelma when&#xD;
      compared with Veltassa and S/CPS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This non-interventional, Phase IV, exploratory, cross-over, randomised, single-blind, active&#xD;
      comparator-controlled study has been designed to measure the palatability and preference of&#xD;
      sodium zirconium cyclosilicate (hereafter referred to as Lokelma®) versus calcium patiromer&#xD;
      sorbitex (hereafter referred to as Veltassa®) versus sodium polystyrene sulphonate (SPS) or&#xD;
      calcium polystyrene sulphonate (CPS) (hereafter referred to as S/CPS) in patients with&#xD;
      dialysis and non-dialysis chronic kidney disease (CKD) and hyperkalaemia (HK). The sponsor&#xD;
      hypothesizes that palatability, in terms of taste, texture, smell, and mouthfeel, will score&#xD;
      higher (better) for Lokelma when compared with Veltassa and S/CPS. Each objective will be&#xD;
      analysed per country. In addition, the difference in results per regions and overall may be&#xD;
      explored.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 23, 2020</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Score (0-10) for overall taste of NIMPs</measure>
    <time_frame>Tasting visit (day 1)</time_frame>
    <description>To compare patient-reported overall taste score between Lokelma and Veltassa, and between Lokelma and S/CPS. 0 = dislike it very much, 10 = like it very much.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Scores for feelings of Appeal, Engagement, and Empowerment regarding taste of NIMPs using the AdSAM tool.</measure>
    <time_frame>Tasting visit (day 1)</time_frame>
    <description>To compare patient-reported emotional score response to taste between Lokelma and Veltassa, and between Lokelma and S/CPS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scoring (0-10) of taste.</measure>
    <time_frame>Tasting visit (day 1)</time_frame>
    <description>To describe patient-reported preference for taste (scoring) of 3 currently marketed K+ binders (Lokelma, Veltassa, S/CPS).&#xD;
0 = dislike it very much, 10 = like it very much.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scoring (0-10) for texture, smell, and mouthfeel.</measure>
    <time_frame>Tasting visit (day 1)</time_frame>
    <description>To describe patient-reported preferences scores for texture, smell and mouthfeel between Lokelma and Veltassa, and between Lokelma and S/CPS.&#xD;
0 = dislike it very much, 10 = like it very much.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scoring (0-10) for willingness to take a K+ binder.</measure>
    <time_frame>Tasting visit (day 1)</time_frame>
    <description>To describe, based on the taste experience (scoring) for how willing patients would be to take each K+ binder to help manage their serum potassium (likelihood of adherence).&#xD;
0 = very unlikely, 10 = very likely.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall preference ranking of NIMPs (1, 2, or 3) of Lokelma, Veltassa, and S/CPS and use of Comparative AdSAM Emotional Strength Index and Emotional Temp</measure>
    <time_frame>Tasting visit (day 1)</time_frame>
    <description>To describe patient-reported preference by ranking the NIMPs, and derived preference based on the emotional strength index.&#xD;
1 = most preferred product, 3 = least preferred product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determining feelings towards the taste of each NIMP using the AdSAM tool</measure>
    <time_frame>Tasting Visit (day 1)</time_frame>
    <description>To describe patient-reported non-verbal emotional response for how the taste of each NIMP made patients feel of each NIMP of 3 current marketed K+ binders (Lokelma, Veltassa, S/CPS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in scores for feelings of Appeal, Engagement, and Empowerment regarding texture, smell, and mouthfeel, respectively, using the AdSAM tool.</measure>
    <time_frame>Tasting Visit (day 1)</time_frame>
    <description>To compare patient-reported emotional response between Lokelma and Veltasse and between Lokelma and S/CPS for attributes including:&#xD;
Texture (oral tactile properties of an NIMP)&#xD;
Smell&#xD;
Mouth feeling (residual feeling in the mouth after consuming [the act of using, eating, drinking, or in this case, tasting] an NIMP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in scores (0-10) for texture, smell, and mouthfeel, respectively</measure>
    <time_frame>Tasting visit (day 1)</time_frame>
    <description>To compare patient-reported scores between Lokelma and Veltassa, and between Lokelma and S/CPS for attributes including:&#xD;
Texture (oral tactile properties of an NIMP)&#xD;
Smell&#xD;
Mouth feeling (residual feeling in the mouth after consuming [the act of using, eating, drinking, or in this case, tasting] an NIMP) 0 = dislike it very much, 10 = like it very much.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scoring (0-10) of texture, smell, and mouthfeel</measure>
    <time_frame>Tasting visit (day 1)</time_frame>
    <description>To describe patient-reported preference (scoring) for attributes: texture, smell, and mouthfeel for each NIMP.&#xD;
0 = dislike it very much, 10 = like very much</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determining feelings of Appeal, Engagement, and Empowerment regarding texture, smell, and mouthfeel using the AdSAM tool</measure>
    <time_frame>Tasting visit (day 1)</time_frame>
    <description>To describe patient-reported preference (emotional response) for attributes: texture, smell, and mouthfeel for each NIMP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determining feelings (Appeal, Engagement and Empowerment) towards willingness to take a K+ binder using the AdSAM tool.</measure>
    <time_frame>Tasting visit (day 1)</time_frame>
    <description>To describe, based on the taste experience and emotional response for how willing patients would be to take each K+ binder to help manage their serum potassium (likelihood of adherence)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Comparative AdSAM Emotional Strength Index and Emotional Temp.</measure>
    <time_frame>Tasting visit (day 1)</time_frame>
    <description>To describe patient-reported preference by ranking the NIMPs, and derived preference based on the emotional strength index.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Overall taste scores (1-10) of all products per region and overall.</measure>
    <time_frame>Tasting visit (day 1)</time_frame>
    <description>To compare overall scores (0-10) between Lokelma and Veltassa, and between Lokelma and S/CPS for all primary and secondary endpoints per region and over all regions.&#xD;
= dislike very much, 10 = like very much</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Chronic Kidney Disease + Hyperkalaemia +/- Heart Failure</condition>
  <arm_group>
    <arm_group_label>dialysis-dependent</arm_group_label>
    <description>chronic kidney disease patients with hyperkalaemia and dialysis-dependent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-dialysis-dependent</arm_group_label>
    <description>chronic kidney disease patients with hyperkalaemia and non-dialysis-dependent</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium Polystyrene Sulphonate 15g/60 mL water</intervention_name>
    <description>K+ binder, not for treatment but for tasting (sip-and-spit taste test)</description>
    <arm_group_label>dialysis-dependent</arm_group_label>
    <arm_group_label>non-dialysis-dependent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lokelma® 5 g/45mL water</intervention_name>
    <description>K+ binder, not for treatment but for tasting (sip-and-spit taste test)</description>
    <arm_group_label>dialysis-dependent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lokelma® 10 g/45 mL water</intervention_name>
    <description>K+ binder, not for treatment but for tasting (sip-and-spit taste test)</description>
    <arm_group_label>non-dialysis-dependent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Veltassa® 8,4 g/80mL water</intervention_name>
    <description>K+ binder, not for treatment but for tasting (sip-and-spit taste test)</description>
    <arm_group_label>dialysis-dependent</arm_group_label>
    <arm_group_label>non-dialysis-dependent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Polystyrene Sulphonate 15g/60 mL water</intervention_name>
    <description>K+ binder, not for treatment but for tasting (sip-and-spit taste test)</description>
    <arm_group_label>dialysis-dependent</arm_group_label>
    <arm_group_label>non-dialysis-dependent</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with dialysis and non-dialysis CKD and HK&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participants must be adults aged ≥18 years, at the time of signing the informed&#xD;
             consent.&#xD;
&#xD;
          2. Participants should have CKD defined by having an estimated glomerular filtration rate&#xD;
             (eGFR) &lt;60 mL/min/1.73 m2 (calculated using CKD-EPI equation) measured twice at least&#xD;
             90 days apart. (The eGFR should be measured when the participant is considered to be&#xD;
             in a steady state without recent changes in volume status, medications that could&#xD;
             impact the result (eg, nonsteroidal anti-inflammatory drugs, aminoglycosides,&#xD;
             co-trimoxazole), or changes in dietary protein intake.)&#xD;
&#xD;
          3. Prevalent HK with serum K+ &gt;5 mmol/L.&#xD;
&#xD;
          4. Male and/or female&#xD;
&#xD;
          5. Capable of giving signed informed consent as described in Appendix A which includes&#xD;
             compliance with the requirements and restrictions listed in the informed consent form&#xD;
             (ICF) and in this protocol. Informed consent must be obtained prior to any&#xD;
             study-specific procedures performed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Screening serum K+ value which, in the opinion of the investigator, requires immediate&#xD;
             medical intervention (ie, cannot wait until after tasting procedures).&#xD;
&#xD;
          2. As judged by the investigator, any evidence of any condition which in the&#xD;
             investigator's opinion makes it undesirable for the participant to participate in the&#xD;
             study.&#xD;
&#xD;
          3. Known history of drug or alcohol abuse within 6 months of screening.&#xD;
&#xD;
          4. History of QT prolongation associated with other medications that required&#xD;
             discontinuation of that medication, including congenital long QT syndrome.&#xD;
&#xD;
          5. Symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic&#xD;
             sustained ventricular tachycardia. Participants with atrial fibrillation controlled by&#xD;
             medication are permitted.&#xD;
&#xD;
          6. Have a life expectancy of &lt;6 months.&#xD;
&#xD;
          7. 12-lead ECG with reported QTcF &gt;550 msec at screening.&#xD;
&#xD;
          8. Are current smoker.&#xD;
&#xD;
          9. Have mouth ulcers/mouth infection, respiratory infection, nasal congestion, or other&#xD;
             condition, medication, or procedure which may interfere with sense of smell or taste,&#xD;
             in opinion of the investigator.&#xD;
&#xD;
         10. Participants currently prescribed a K+ binder at time of screening/enrolment.&#xD;
&#xD;
         11. Participants unable to hold other oral medications from 3 hours prior to the start of&#xD;
             tasting through 3 hours after the end of tasting.&#xD;
&#xD;
         12. Current participation or participation within the previous 28 days in another clinical&#xD;
             study with an investigational product administered.&#xD;
&#xD;
         13. Participants with a known hypersensitivity to Lokelma, Veltassa, or S/CPS or any of&#xD;
             the excipients of the NIMPs.&#xD;
&#xD;
         14. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca&#xD;
             staff and/or staff at the study site).&#xD;
&#xD;
         15. Judgment by the investigator that the participant should not participate in the study&#xD;
             if the participant is unlikely to comply with study procedures, restrictions and&#xD;
             requirements.&#xD;
&#xD;
         16. Previous enrolment or randomisation in the present study.&#xD;
&#xD;
         17. For women only - currently pregnant (confirmed with positive pregnancy test) or&#xD;
             breast-feeding.&#xD;
&#xD;
         18. Participants unable to read the local language and therefore unable to complete the&#xD;
             questionnaires.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>130 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Wittbrodt, PharmD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca, Biopharmaceuticals Medical</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308-5204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Temple Terrace</city>
        <state>Florida</state>
        <zip>33637-0935</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec City,QC</state>
        <zip>J4V 2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec City,QC</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quebec</city>
        <state>Quebec City,QC</state>
        <zip>GIL 3L5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amiens Cedex 1</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boulogne-Billancourt</city>
        <zip>92100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nice Cedex 1</city>
        <zip>6001</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Villingen-Schwenningen</city>
        <state>BW</state>
        <zip>78052</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Munchen</city>
        <state>BY</state>
        <zip>80804</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tuebingen</city>
        <zip>7207</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bari</city>
        <state>BA</state>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Acireale</city>
        <state>GE</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Piacenza</city>
        <state>PC</state>
        <zip>29121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Parma</city>
        <state>PR</state>
        <zip>43126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pavia</city>
        <state>PV</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cordoba</city>
        <state>CO</state>
        <zip>14005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>A Coruna</city>
        <state>C</state>
        <zip>15009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lleida</city>
        <state>L</state>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <state>M</state>
        <zip>28031</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santa Cruz De Tenerife</city>
        <state>TF</state>
        <zip>38010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Danderyd</city>
        <state>AB</state>
        <zip>182 57</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Malmo</city>
        <state>M</state>
        <zip>214 28</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uppsala</city>
        <zip>750 02</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.adsam.com/</url>
    <description>AdSAM Emotional Response Modelling website. AdSAM Measure.</description>
  </link>
  <link>
    <url>https://academic.oup.com/ndt/advance-article/doi/10.1093/ndt/gfy249/5067140</url>
    <description>Gasparini A, Evans M, Barany P, Xu H, Jernberg T, Ärnlöv J, et al. Plasma potassium ranges associated with mortality across stages of chronic kidney disease: the Stockholm CREAtinine Measurements (SCREAM) project. Nephrol Dial Transplant. 2018;(Aug):1-8.</description>
  </link>
  <link>
    <url>http://www.nejm.org/doi/10.1056/NEJMe1414112</url>
    <description>Ingelfinger JR. A new era for the treatment of hyperkalemia? N Engl J Med [Internet]. 2015 Jan 15;372(3):275-7.</description>
  </link>
  <link>
    <url>https://www.sciencedirect.com/science/article/pii/S0002934315005410?via%3Dihub</url>
    <description>Kovesdy CP. Management of hyperkalemia: An update for the internist [Internet]. Vol. 128, American Journal of Medicine. Elsevier; 2015 [cited 2019 Feb 18]. p. 1281-7.</description>
  </link>
  <link>
    <url>http://www.nejm.org/doi/10.1056/NEJMoa1411487</url>
    <description>Packham DK, Rasmussen HS, Lavin PT, El-Shahawy MA, Roger SD, Block G, et al. Sodium Zirconium Cyclosilicate in Hyperkalemia. N Engl J Med [Internet]. 2015;372(3):222-31.</description>
  </link>
  <link>
    <url>http://dx.doi.org/10.1016/j.cocis.2013.04.010</url>
    <description>Stokes JR, Boehm MW, Baier SK. Oral processing, texture and mouthfeel: From rheology to tribology and beyond. Curr Opin Colloid Interface Sci [Internet]. 2013;18(4):349-59.</description>
  </link>
  <link>
    <url>https://doi.org/10.1016/0924-2244(96)10025-X</url>
    <description>Guinard JX, Mazzucchelli R. The sensory perception of texture and mouthfeel. Trends Food Sci Technol. 1996;7(7):213-9</description>
  </link>
  <link>
    <url>https://doi.org/10.2501/JAR-42-3-7-17</url>
    <description>Morris JD, Woo C, Geason JA, and Kim J. The power of affect: predicting intention. Journal of Advertising Research. 2002;42(3):7-17.</description>
  </link>
  <reference>
    <citation>Thomsen RW, Nicolaisen SK, Hasvold P, Sanchez RG, Pedersen L, Adelborg K, Egstrup K, Egfjord M, Sørensen HT. Elevated potassium levels in patients with chronic kidney disease: occurrence, risk factors and clinical outcomes-a Danish population-based cohort study. Nephrol Dial Transplant. 2018 Sep 1;33(9):1610-1620. doi: 10.1093/ndt/gfx312.</citation>
    <PMID>29177463</PMID>
  </reference>
  <reference>
    <citation>Laureati P, Xu Y, Trevisan M, Schalin L, Mariani I, Bellocco R, Sood MM, Barany P, Sjölander A, Evans M, Carrero JJ. Initiation of sodium polystyrene sulphonate and the risk of gastrointestinal adverse events in advanced chronic kidney disease: a nationwide study. Nephrol Dial Transplant. 2020 Sep 1;35(9):1518-1526. doi: 10.1093/ndt/gfz150.</citation>
    <PMID>31377791</PMID>
  </reference>
  <reference>
    <citation>Noel JA, Bota SE, Petrcich W, Garg AX, Carrero JJ, Harel Z, Tangri N, Clark EG, Komenda P, Sood MM. Risk of Hospitalization for Serious Adverse Gastrointestinal Events Associated With Sodium Polystyrene Sulfonate Use in Patients of Advanced Age. JAMA Intern Med. 2019 Aug 1;179(8):1025-1033. doi: 10.1001/jamainternmed.2019.0631. Erratum in: JAMA Intern Med. 2020 Feb 24;:.</citation>
    <PMID>31180477</PMID>
  </reference>
  <reference>
    <citation>Zann V, McDermott J, Jacobs JW, Davidson JP, Lin F, Korner P, Blanks RC, Rosenbaum DP. Palatability and physical properties of potassium-binding resin RDX7675: comparison with sodium polystyrene sulfonate. Drug Des Devel Ther. 2017 Sep 6;11:2663-2673. doi: 10.2147/DDDT.S143461. eCollection 2017.</citation>
    <PMID>28919716</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 31, 2020</study_first_submitted>
  <study_first_submitted_qc>September 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2020</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>palatability</keyword>
  <keyword>Lokelma</keyword>
  <keyword>hyperkalaemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Hyperkalemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Polystyrene sulfonic acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.&#xD;
All request will be evaluated as per the AZ disclosure commitment:&#xD;
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.</ipd_description>
    <ipd_time_frame>AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_time_frame>
    <ipd_access_criteria>When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_access_criteria>
    <ipd_url>https://astrazenecagroup-dt.pharmacm.com/DT/Home</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

